Review

Current Status of Autoimmune Hepatitis in Japan

Yasuhiro Miyake*, and Kazuhide Yamamoto

*Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, Okayama 700–8558, Japan*

Autoimmune hepatitis (AIH) is a chronic and progressive disease characterized by histological inter-face hepatitis, hypergammaglobulinemia, and circulating autoantibodies. Multiple factors, including molecular mimicry, a genetic background including major histocompatibility complex class II, and defective function of regulatory T-cells, are involved in the pathogenesis. The diagnosis is made based on the scoring system of the International Autoimmune Hepatitis Group, the sensitivity and specificity of which are > 90%, respectively. AIH is classified into 3 sub-types based on the profiles of circulating autoantibodies: anti-nuclear antibody and/or smooth muscle antibody-positive (type 1), anti-liver-kid-ney microsomal antibody-positive (type 2), and anti-soluble liver antigen/liver-pancreas antigen anti-body-positive (type 3). Recently, however, the number of atypical cases lacking the usual features has increased—for example, patients with acute-onset or fulminant-type AIH, autoantibody-negative patients, male patients, and patients with bile duct injury—and thus the clinical features of AIH have been diversified. AIH is responsive to immunosuppressive treatment in most cases; however, relapse occurs in more than 80% of patients within 1 year after immunosuppressive treatment withdrawal. The 10-year survival rate and the 10-year hepatocellular carcinoma-free rate are > 90%, respectively, indicating that some patients reach liver failure or develop hepatocellular carcinoma. To improve the prognosis of these patients, persistent normalization of transaminase is required.

Key words: autoimmune hepatitis, epidemiology, pathogenesis, diagnosis, prognosis

Autoimmune hepatitis (AIH), first reported by Waldenström in 1950 [1], is a chronic and progressive disease characterized by histological inter-face hepatitis, hypergammaglobulinemia, and circulat-ing autoantibodies [2]. The prognosis of AIH is gen-erally good with immunosuppressive treatment, but some patients may develop hepatocellular carcinoma (HCC) or liver failure [3, 4].

There has been considerable uncertainty about the

diagnostic criteria for AIH since identification of the hepatitis C virus (HCV) in 1989 [5]. Anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), and anti-liver-kidney microsomal type 1 antibody (LKM-1), which are important factors for the diagno-sis of AIH, are found in 9%, 20%, and 6% of chronic hepatitis C (CHC) cases, respectively, and the overall prevalence of autoantibodies is 30% [6]. Furthermore, CHC patients with autoantibodies have more severe portal-periportal necroinflammation than those without autoantibodies [6]. To establish diag-nostic criteria for AIH, a scoring system was pro-posed by the International Autoimmune Hepatitis

Group (IAHG) in 1993 [7]. The sensitivity of this scoring system was more than 90%, while the specificity was insufficient, especially in patients with primary sclerosing cholangitis (PSC) [8], so the scoring system was modified in 1999 [8].

Recently, atypical cases lacking the usual features of AIH has also been reported [9–12], with the result that the clinical features of AIH have been diversified. Herein, we review the current status of autoimmune hepatitis.

Pathogenesis

A mechanism of molecular mimicry between foreign and self-antigens is considered to be one of the major sources of pathogenesis in AIH. Several drugs (infliximab, minocycline, atorvastatin, hepatitis A vaccine) and viruses (hepatitis A virus, hepatitis B virus, HCV, Epstein-Barr virus) have been reported as possible triggers for AIH [13–20]. In the molecular mimicry theory, self-reactive T cells, initially activated by infectious pathogens, subsequently provoke a self-destructive response in an organ expressing a cross-reactive self-Ag. For example, in patients with HCV infection, molecular mimicry at the B cell level has been shown between CYP2D6, which is an enzyme targeted by LKM-1 autoantibodies, and the HCV NS3 and NS5a proteins [21]. On the other hand, the development of AIH is associated with genetic background in patients with acute infection of hepatitis A virus and Epstein-Barr virus [20, 22]. Defective suppressor-inducer T cell function may provoke helper T cell activation and antibody production against asialoglycoprotein receptors (ASGPR) and thereby leading to the development of AIH type 1.

Genetic background is an important factor, and individuals with certain major histocompatibility complex (MHC) class II alleles are susceptible to AIH, as in other autoimmune diseases. MHC class II plays an important role in antigen presentation, because peptide antigens are recognized by CD4 T cells in association with MHC class II and types of peptides are determined by the amino acid sequence in the groove of MHC class II. After exposure to foreign antigens, individuals with a certain MHC class II present specific peptides showing molecular mimicry to self antigens, and this may trigger an autoimmune reaction against self antigens. For example, certain amino acid residues of human leukocyte antigen (HLA)-DRβ molecules (Lys71 in Caucasian patients with DRB1*0301 and DRB1*0401 and Arg71 in Japanese patients with DRB1*0405) have been reported to contribute to the susceptibility to AIH [23, 24]. This residue 71 of the DRβ molecule, which is located on top of the α-helix pointing into the peptide-binding groove, may influence peptide binding, orientation, and interaction with the T cell receptor. However, the types of self antigens presented by MHC class II in AIH type 1 have not been clarified.

It has recently been postulated that CD4$^+$ CD25$^+$ regulatory T cells play a role in the pathogenesis of AIH. CD4$^+$ CD25$^+$ regulatory T cells maintain immunological tolerance and suppress autoreactive immune responses. A genetic or acquired defective function of regulatory T cells may cause excessive autoimmune reactions. In patients with AIH, CD4$^+$ CD25$^+$ regulatory T cells are numerically and functionally defective, and the percentage of CD8$^+$ T cells spontaneously undergoing apoptosis is lower than in normal controls [25, 26]. Furthermore, in patients with AIH, Foxp3 expression in CD4$^+$ CD25$^+$ regulatory T cells is lower than in normal controls. Circulating CD4$^+$ CD25$^+$ regulatory T cells increase during early pregnancy, peaking during the second trimester and decreasing postpartum [27]. In contrast, the activity of AIH declines during early pregnancy and flares after delivery [28]. The inverse correlation between CD4$^+$ CD25$^+$ T cells and clinical activity may support the hypothesis that activation of autoreactive CD8$^+$ T cells under the condition of defective CD4$^+$ CD25$^+$ regulatory T cells may play a role in the pathogenesis of AIH.

Diagnosis

In Japan, AIH has been diagnosed based on the criteria proposed by the Intractable Hepatitis Study Group of the Ministry of Health and Welfare of Japan (Japanese criteria) (Table 1) [29]. The criteria consist of hypergammaglobulinemia (or IgG concentration ≥ 2.5 g/dL), circulating autoantibody (ANA- and/or SMA-positive), histological features (plasma cell infiltration, interface hepatitis, and hepatocyte necrosis), and exclusion of other known causes of chronic hepatitis (viruses, alcohol, drugs, Wilson's disease, hemochromatosis, α1-antitrypsin deficiency, etc.).

Recently, a revised IAHG scoring system was proposed as a useful diagnostic tool in clinical practice (Table 2) [8]. Papamichalis et al. [30] applied the scoring system to 423 patients with liver diseases excluding AIH and reported that the specificity was 98%. In another study applying the scoring system to PSC patients, the specificity was 93% [31]. Omagari et al. [32] applied the scoring system to 89 patients who fulfilled the Japanese criteria and reported that the sensitivity was 91%. The scoring system was also reported to be useful for pediatric patients with AIH [33].

The revised IAHG scoring system thus seems to be sufficiently accurate for the diagnosis of AIH, but there have been some difficulties in applying it to atypical forms of diseases. Farias et al. [34] reported that only 28% of patients with antimitochondrial antibody (AMA)-positive AIH had scores high enough for a definite diagnosis. On the other hand, Yatsuji et al. [35] reported that, in female patients with nonalcoholic fatty liver disease, 97% had a score of 10 or more without including the liver biopsy results. Furthermore, Hayashi et al. [36] reported that in the general Japanese population, the rates of ANA-positive samples at 1: 40 and 1: 160 dilutions were 26% and 10%, respectively, with females having a significantly higher positive rate than males. These findings indicate that low titers of ANA may not be sufficiently specific for a diagnosis of AIH, and thus AIH diagnosis requires a liver biopsy.

Patients with AIH are classified into 3 sub-types based on profiles of circulating autoantibodies. AIH type 1 is a classical type, so-called lupoid hepatitis. It is associated with ANA and/or SMA. In Japanese, it is dominantly associated with HLA-DRB1* 0405; however, DRB1*0405 does not influence the clinical features [37]. In Caucasians, AIH type 1 is primarily associated with DRB1*0301 and secondarily with DRB1*0401 [38]. Patients with DRB1* 0301 differ from those with DRB1*0401 in that they are younger and fail treatment more commonly [39]. On the other hand, DRB1*0401 is associated with a

Table 1   Criteria for diagnosis of autoimmune hepatitis in Japan. The Study Group of the Japanese Ministry of Health and Welfare (29).

General concept

Increased prevalence in younger females, chronic active hepatitis with potential progression to cirrhosis, existence of autoimmune mechanisms in etiology, exclusion of all other known specific causes of chronic hepatitis, such as viruses, alcohol, drugs, etc. good response to corticosteroid therapy (typical).

Ⅰ. **Major findings**
  1. Persistent elevation of serum aminotransferases
  2. Hypergammaglobulinemia of 2.5 g/dL or greater (or IgG concentration of 2.5 g/dL or greater)
  3. Circulating autoantibody: a) and/or b)
      a) LE test-positive
      b) ANA (antinuclear antibody)-positive and/or LE test-positive
  4. IgM anti-HAV (hepatitis A virus)-negative and absence of other evidence of HBV infection (HBs antigen-negative, anti-HBc antibody-negative or at low titers)
  5. Absence of true-positive anti-HCV antibody or other evidence of HCV infection

Ⅱ. **Minor findings**
  1. Systemic manifestations such as fever, arthralgia, and skin eruption
  2. Complications of other autoimmune diseases including collagen disease
  3. a) and/or b)
      a) Accelerated ESR (erythrocyte sedimentation rate) at 30 mm/h or faster
      b) C-reactive protein (CRP)-positive

Ⅲ. **Histology**

  Chronic active hepatitis or cirrhosis with marked plasma cell infiltration and hepatocyte necrosis, absence of features of other specific diagnosis such as α-1-antitrypsin deficiency

Diagnosis of autoimmune hepatitis
  1) Diagnostic: Fulfill all criteria of Ⅰ and Ⅲ
  2) Suggestive: Fulfill all criteria of Ⅰ and at least one of Ⅱ
  3) Possible: Fulfill all criteria of Ⅰ

Table 2 Revised scoring system for autoimmune hepatitis. International Autoimmune Hepatitis Group (8).

Parameters/Features	Score
Female sex	+2
ALP: AST (or ALT) ratio:	
< 1.5	+2
1.5–3.0	0
> 3.0	−2
ANA, SMA or LKM-1	
> 1: 80	+3
1: 80	+2
1: 40	+1
< 1: 40	0
AMA-positive	−4
Hepatitis viral markers:	
Positive	−3
Negative	+3
Drug history:	
Positive	−4
Negative	+1
Average alcohol intake	
< 25 g/day	+2
> 60 g/day	−2
Liver histology:	
Interface hepatitis	+3
Predominantly lymphoplasmacytic infiltrate	+1
Rosetting of liver cells	+1
None of the above	−5
Biliary changes	−3
Other changes	−3
Other autoimmune disease	+2
Optional additional parameters:	
Seropositive for other defined autoantibodies (perinuclear staining antineutrophil cytoplasmic antibody, anti-liver specific cytosolic antigen, anti-soluble liver antigen, anti-hepatic asialoglycoprotein receptor, anti-liver-pancreas antigen, and anti-sulfatide)	+2
HLA DR3 or DR4	+1
Response to therapy:	
Complete	+2
Relapse	+3
Interpretation of aggregate scores:	
Pre-treatment:	
Definite AIH	> 15
Probable AIH	10–15
Post-treatment	
Definite AIH	> 17
Probable AIH	12–17

lower frequency of death from liver failure or the need for transplantation.

AIH type 2 is characterized by LKM-1 autoantibodies and/or anti-liver cytosol antibody type 1 (LC1) [40]. The serum LC1 concentration, at variance with that of LKM-1, parallels liver disease activity [41]. Recently, the HLA-DQB1*0201 allele was reported to be the primary genetic determinant of susceptibility to AIH type 2 [42]. The onset resembles acute viral hepatitis with marked elevation of transaminase and hypergammaglobulinemia [40]. Patients with AIH type 2 require prolonged treatment with corticosteroids and immunosuppressants.

AIH type 3 is characterized by the presence of antibody to soluble liver antigen/liver-pancreas antigen (SLA/LP) [43]. Patients with AIH type 3 tend to have lower levels of transaminase, gamma globulin, and bilirubin in comparison to patients with AIH type 1 [44]. Response to immunosuppressive therapy is excellent, but relapses occur frequently.

Atypical Forms of AIH

AIH predominantly affects women, and the clinical characteristics are different between females and males. Among Caucasian patients, the male patients are distinguished from the females by lower frequencies of concurrent autoimmune disease (17% vs. 34%) and HLA DR4 (24% vs. 49%) [45]. Treatment failure occurs more frequently in male patients only if they have HLA DR3. Furthermore, male patients experience relapse more frequently. Among Japanese patients, compared with females, males have a lower frequency of definite diagnosis according to the revised scoring system and lower serum levels of immunoglobulin G [10]. However, Japanese male and female AIH patients are similar in age, form of clinical onset, symptomatic concurrent autoimmune disease, and HLA-DR status. The response to corticosteroid treatment is better in female patients than in males.

Recently, reports on acute onset of AIH have increased, and 26% of Japanese patients have been reported to show acute onset [9]. Patients with acute onset have lower serum levels of albumin, gamma globulin, and immunoglobulin G, and higher serum levels of total bilirubin, AST, and ALT, and more frequently show moderate to severe lobular hepatitis; however, acute onset reflects not only acute AIH but also acute exacerbation of pre-existing chronic disease. On the other hand, patients with acute liver failure have been reported occasionally.

Corticosteroid treatment is of little benefit to patients with acute liver failure, and most of them require liver transplantation [46]. However, low titer autoantibodies are frequently detected in cases of acute liver failure, and the diagnosis of acute liver failure due to autoimmune hepatitis should be made carefully [47].

Bile duct injury, which is characteristic of primary biliary cirrhosis (PBC), is an important condition to consider in patients with AIH. There has been one report of a patient with chronic nonsuppurative destructive cholangitis-like bile duct injuries who did not respond to ursodeoxycholic acid (UDCA) but did respond to prednisolone [48]. In one study, bile duct injury was present in 24% of patients negative for AMA, and 7% had destructive cholangitis [12]. There are no differences in clinical characteristics, including response to immunosuppressive treatment, between patients with and without bile duct injury. Furthermore, there is no difference in the concurrence of inflammatory bowel disease. Recently, 10% of AIH patients have been reported to have magnetic resonance cholangiography findings consistent with PSC [49]. It has been controversial whether these bile duct injuries are histological features of AIH or those of an overlap of AIH and PBC or PSC.

Clinical Features of Japanese AIH

In recent reports from Japan, approximately 10% of AIH patients were male, and the peak incidence was between ages 50 and 60 years in both male and female patients. Approximately 95% of cases were positive for ANA and/or SMA [29, 50]. In a histological analysis, 85% of patients showed interface hepatitis, and rosetting of liver cells was seen in 28% of cases [9]. In the same histological analysis, zone III necrosis was seen in 29% of cases, and acute hepatitis and cirrhosis were diagnosed in 6% and 10% of patients, respectively, at presentation [9]. Concurrent autoimmune diseases (autoimmune thyroiditis, Graves' disease, Sjögren's syndrome, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, rheumatoid arthritis, autoimmune hemolytic anemia, etc.) were found in 24% of AIH patients [9]. Positivity for HLA-DR4 was seen in 75% of cases, and there were no patients with DR3 [29]. In other studies, patients negative for DR4 were mainly positive for DR2; however, the frequency of DR2 was similar between patients with AIH and healthy controls [37, 51]. These studies also demonstrated that the proportion of patients with DR4 was low among patients aged < 30 years. Interestingly, concurrence of thyroid disease (autoimmune thyroiditis, Graves' disease) is reported to be associated with DR4 [51]. There are some notable differences in clinical features between Japanese and Caucasian patients with AIH (Table 3). In Japanese patients compared with Caucasian patients, proportions of patients aged < 40 years, male patients, and patients with histological cirrhosis are smaller [29, 52–55]. In Caucasian patients, those with HLA DR3 and DR4 are independently susceptible to autoimmune hepatitis [56], while DR4 is predominant in Japanese patients and there are no Japanese patients with DR3 [29]. Patients with DR3 have an earlier age of onset, and they deteriorate during corticosteroid treatment, die of liver failure, and require liver transplantation more often than those with DR4 [39, 57]. Female patients have DR4 more frequently than do males

Table 3   Comparison of clinical features between Japanese patients and Caucasian patients with AIH type 1 (8, 10, 29, 45, 50–52, 79–81).

	Japanese patients	Caucasian patients
Peak age at presentation	50–70	40–70
Male patients (%)	12–13	21–22
ANA positive (%)	84–95	72–79
SMA positive (%)	64	69–75
ANA and/or SMA positive (%)	95–99	97
Main HLA-DR (%)	DR4 (70–75)	DR3 (51–57), DR4 (43–49)
Concurrent autoimmune disease (%)	24	30–31
Autoimmune thyroiditis (%)	11	13–15
Cirrhosis at presentation (%)	10–12	27–34

[45]. On the other hand, patients with DR4 are older and respond better to corticosteroid treatment. The differences in clinical features are considered to be due to the HLA-DR status.

Treatment

In the practice guidelines of the American Association for the Study of Liver Diseases, patients with serum AST levels ≥ 10-fold the upper limit of normal or with serum AST ≥ 5-fold the upper limit of normal in conjunction with a serum gamma globulin level at least twice the upper limit of normal are recommended for immunosuppressive treatment [58]. However, to improve their prognosis, persistent normalization of transaminase is required [3, 4]. Thus, patients with abnormal levels of transaminase should receive some treatments.

In a study of Japanese patients, normalization of ALT at 6 months after the introduction of initial treatment was achieved in 89% of patients treated with corticosteroid, 100% of patients treated with azathioprine, and 51% of patients treated with UDCA [29]. On the other hand, in a study of Caucasian patients, 76% of those without cirrhosis at presentation and 78% of those with cirrhosis achieved remission by corticosteroid alone or a combination of corticosteroid and azathioprine [55]. Furthermore, the frequencies of patients who fail corticosteroid treatment are reported to be 7–14%, and onset at an early age, acute presentation, hyperbilirubinemia, and presence of HLA DRB1*03 are associated with treatment failure [55, 59]. Together, these findings indicate that Japanese patients show a favorable response to corticosteroid treatment compared with Caucasian patients.

In a study by Montano-Loza et al., relapse is seen in 86% of AIH patients within 1 year after initial treatment withdrawal [60]. Approximately 50% of these patients relapse within 3 months. Portal plasma cell infiltration in the liver biopsy specimens is predictive of relapse after drug withdrawal [61]. Serum levels of gamma globulin and immunoglobulin G are higher in patients with relapse compared with those with sustained remission [62]. There is no difference in frequencies of relapse after drug withdrawal between patients with and without cirrhosis at presentation. Patients should be treated to achieve normal serum

levels of transaminase, gamma globulin, and immunoglobulin G. On the other hand, patients who respond to initial corticosteroid treatment can achieve a sustained remission after treatment withdrawal or after relapse and re-treatment [63].

Corticosteroid.   In most patients, prednisolone has been successfully used alone or in combination with azathioprine. In Caucasian patients, prednisolone is initially administered at a dose of 60 mg daily or at a dose of 30 mg daily in combination with azathioprine at 50 mg daily [58]. In Japanese patients, prednisolone monotherapy (30–40 mg/day) or a combination of prednisolone (20–40 mg daily) and azathioprine (50–100 mg daily) is generally performed. In Japanese patients with histological low-grade inflammatory activity, prednisolone at 20 mg daily may be sufficient [3, 4]. Prednisolone is tapered over 6–8 weeks to 5–10 mg daily and should be continued for at least 2 years after the achievement of the normalization of transaminase [58]. Concerning the long-term side effects of corticosteroid, Seela et al. [64] have reported that, for a median follow-up of 13.5 years, weight gain, cushingoid feature, and steroid-related osteoporosis were seen in 21%, 7%, and 5% of patients, respectively, although none developed steroid-induced diabetes.

Azathioprine.   Azathioprine at 50 mg daily is used in combination with prednisolone as an initial treatment [58]. In patients whose clinical, laboratory, or histological findings worsen despite conventional treatment, azathioprine at 150 mg daily in combination with prednisolone is recommended [58]. Furthermore, Johnson et al. [65] reported that, among patients who had achieved remission with a combination treatment of prednisolone and azathioprine and then continued to receive 2 mg/kg azathioprine daily after withdrawal of prednisolone, 83% remained in remission for a median follow-up of 67 months. The use of azathioprine during pregnancy is reported to be relatively safe [66, 67]. The side effects of azathioprine include cholestatic hepatitis, veno-occlusive disease, pancreatitis, severe nausea, and bone marrow suppression. Bone marrow suppression occurs more frequently in cirrhotic patients than non-cirrhotic patients [68, 69].

Ursodeoxycholic acid.   UDCA treatment improves serum transaminase levels in patients with AIH type 1, but changes of histological activity before

and after UDCA treatment have been controversial [70, 71]. Furthermore, the duration from the introduction of initial treatment to the normalization of serum ALT levels is longer in UDCA treatment compared with corticosteroid treatment [52]. UDCA treatment should be performed in patients who are not candidates for corticosteroid treatment because of comorbidities such as osteoporosis and diabetes or patients with histological low-grade inflammatory activity and sufficient residual capacity of liver function.

Liver transplantation.   Patients who fail immunosuppressive treatment proceed to hepatic failure and require liver transplantation. The 5-year survival rate after liver transplantation has been reported to be 78–100% [72–74]. However, in 41% of patients followed for more than 10 years after liver transplantation, AIH has been reported to recur [75].

Prognosis

In patients with AIH type 1, appropriate treatment improves histological fibrosis, even if cirrhosis is also present [76]. In Caucasians, the prognosis of AIH type 1 has been reported to be similar to that of an age- and sex-matched cohort of disease-free controls from the general population [55]. The 10-year survival has been reported as 89% and 90% in Caucasian patients with and without cirrhosis at presentation, respectively. Similarly, the prognosis of Japanese patients with AIH type 1 is generally good with corticosteroid treatment. The 10-year survival rate and the 10-year HCC-free rate have been reported as 98% and 93%, respectively [3]. On the other hand, the number of patients with AIH type 1 complicated by HCC has increased [77, 78]. Long-standing cirrhosis has been recognized as a risk factor for HCC development. The starting dose of corticosteroid (dose of prednisolone < 20 mg/day), relapse within 3 months after the normalization of serum ALT levels with initial treatment, and elevated serum ALT levels during the follow-up period (> 40 IU/L) have all been significantly correlated with progression of the disease [4]. In particular, elevated serum ALT levels during the follow-up period are associated with HCC development and fatal outcome [3]. Thus, the maintenance of normal serum ALT levels will improve patient prognosis.

Concluding Remarks

AIH is a chronic progressive liver disease caused by an autoimmune mechanism. Although the precise mechanism remains to be fully clarified, multiple factors such as molecular mimicry, a genetic background including HLA class II, and defective regulatory T cell function are involved in the pathogenesis of AIH. Typical clinical features include histological interface hepatitis, hypergammaglobulinemia, and circulating autoantibodies, but patients with atypical forms have been recognized and thus the clinical features have been diversified. Immunosuppressive treatments including corticosteroid and/or azathioprine are effective, and the long-term prognosis is good. UDCA is also effective but needs further evaluation for the long-term prognosis. Liver transplantation is the indicated treatment for patients with hepatic failure, though AIH recurs in 41% of patients after liver transplantation.

References

1. Waldenström L: Leber, Blutprotein und Narungseiweisse. Dtsch Gesellsch Verd Stroffw (1950) 15: 113–119.
2. Krawitt EL: Autoimmune hepatitis. N Engl J Med (2006) 354: 54–66.
3. Miyake Y, Iwasaki Y, Terada R, Okamoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K and Shiratori Y: Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther (2006) 24: 1197–1205.
4. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K and Shiratori Y: Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol (2005) 43: 951–957.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW and Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244: 359–362.
6. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D and Bianchi FB: Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology (1997) 26: 561–566.
7. Johnson PJ and McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology (1993) 18: 998–1005.
8. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR,

MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Mieli-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D and Zeniya M: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 31: 929–938.

9. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K and Shiratori Y: Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res (2007) 37: 801–805.

10. Miyake Y, Iwasaki Y, Sakaguchi K and Shiratori Y: Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther (2006) 24: 519–523.

11. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, Sakaguchi K and Shiratori Y: Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther (2006) 23: 1347–1353.

12. Czaja AJ and Carpenter HA: Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology (2001) 34: 659–665.

13. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R and Valesini G: Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis (2005) 64: 1519–1520.

14. Goldstein NS, Bayati N, Silverman AL and Gordon SC: Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol (2000) 114: 591–598.

15. Pelli N and Setti M: Atorvastatin as a trigger of autoimmune hepatitis. J Hepatol (2004) 40: 716.

16. Berry PA and Smith-Laing G: Hepatitis A vaccine associated with autoimmune hepatitis. World J Gastroenterol (2007) 13: 2238–2239.

17. Huppertz HI, Treichel U, Gassel AM, Jeschke R and Meyer zum Büschenfelde KH: Autoimmune hepatitis following hepatitis A virus infection. J Hepatol (1995) 23: 204–208.

18. Zizer E, Hasel C, Seufferlein T, Adler G and Dikopoulos N: A 40-Year-old female patient with seronegative autoimmune hepatitis following a newly acquired hepatitis B infection. Z Gastroenterol (2008) 46: 201–205 (in German).

19. Vento S, Cainelli F, Renzini C and Concia E: Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet (1997) 350: 1298–1299.

20. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T and Concia E: Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet (1995) 346: 608–609.

21. Marceau G, Lapierre P, Béland K, Soudeyns H and Alvarez F: LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology (2005) 42: 675–682.

22. Vento S, Garofano T, Di Perri G, Dolci L, Concia E and Bassetti D: Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet (1991) 337: 1183–1187.

23. Czaja AJ and Donaldson PT: Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev (2000) 174: 250–259.

24. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston AL, Mowat AP and Williams R: Allelic sequence variation in the HLA

class II genes and proteins in patients with autoimmune hepatitis. Hepatology (1994) 19: 609–615.

25. Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, Mieli-Vergani G and Vergani D: Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun (2005) 25: 63–71.

26. Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, Ma Y: Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol (2006) 176: 4484–4491.

27. Somerset DA, Zheng Y, Kilby MD, Sansom DM and Drayson MT: Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 112: 38–43.

28. Buchel E, Van Steenbergen W, Nevens F and Fevery J: Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol (2002) 97: 3160–3165.

29. Toda G, Zeniya M, Watanabe F, Imawari M, Kiyosawa K, Nishioka M, Tsuji T and Omata M: Present status of autoimmune hepatitis in Japan--correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol (1997) 26: 1207–1212.

30. Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, Mamaloudis I, Gabeta S, Rigopoulou EI, Lohse AW and Dalekos GN: The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 4: 3–14.

31. Kaya M, Angulo P and Lindor KD: Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol (2000) 33: 537–542.

32. Omagari K, Masuda J, Kato Y, Nakata K, Kanematsu T, Kusumoto Y, Mori I, Furukawa R, Tanioka H, Tajima H, Koga M, Yano M and Kohno S: Re-analysis of clinical features of 89 patients with autoimmune hepatitis using the revised scoring system proposed by the International Autoimmune Hepatitis Group. Intern Med (2000) 39: 1008–1012.

33. Ebbeson RL and Schreiber RA: Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin Gastroenterol Hepatol (2004) 2: 935–940.

34. Farias AQ, Gonçalves LL, Bittencourt PL, De Melo ES, Abrantes-Lemos CP, Porta G, Nakhle MC, Carrilho FJ and Cancado EL: Applicability of the IAIHG scoring system to the diagnosis of anti-mitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J Gastroenterol Hepatol (2006) 21: 887–893.

35. Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K and Shiratori K: Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol (2005) 40: 1130–1138.

36. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, Kawano S and Kumagai S: Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol (2008) 18: 153–160.

37. Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, Ando A, Tsuji K, Inoko H and Kiyosawa K: HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology (1992) 103: 1041–1047.

38. Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore

SB, Czaja AJ and Williams R: Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology (1997) 112: 2028–2235.

39. Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT and Williams R: Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology (1997) 25: 317–323.

40. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Lévy VG, Grippon P, Opolon P, Bernuau J, Benhamou JP and Alagille D: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1987) 7: 1333–1339.

41. Muratori L, Cataleta M, Muratori P, Lenzi M and Bianchi FB: Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut (1998) 42: 721–726.

42. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D and Alvarez F: HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol (2006) 45: 844–850.

43. Manns M, Gerken G, Kyriatsoulis A, Staritz M and Meyer zum Büschenfelde KH: Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet (1987) 1: 292–294.

44. Kanzler S, Weidemann C, Gerken G, Löhr HF, Galle PR, Meyer zum Büschenfelde KH and Lohse AW: Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol (1999) 31: 635–640.

45. Czaja AJ and Donaldson PT: Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol (2002) 97: 2051–2057.

46. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D and Samuel D: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl (2007) 13: 996–1003.

47. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J and Vergani D: The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol (2007) 47: 664–670.

48. Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H and Nakanuma Y: Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol Int (2002) 52: 478–482.

49. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M and Heathcote EJ: Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology (2008) 47: 949–957.

50. Miyake Y, Iwasaki Y, Terada R, Nagano T, Kobashi H, Sakaguchi K and Shiratori Y: A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis. Hepatol Res (2008) 38: 658–663.

51. Miyake Y, Iwasaki Y, Takaki A, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K and Shiratori Y: Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis. Hepatol Res (2008) 38: 96–102.

52. Miyake Y, Iwasaki Y, Takaki A, Kobashi H, Sakaguchi K and Shiratori Y: Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med (2007) 46: 1945–1949.

53. Czaja AJ and Carpenter HA: Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology (2006) 43: 532–538.

54. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W and Fevery J: Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther (2005) 21: 695–699.

55. Roberts SK, Therneau TM and Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology (1996) 110: 848–857.

56. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ and Williams R: Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology (1991) 13: 701–706.

57. Czaja AJ, Carpenter HA, Santrach PJ and Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology (1993) 105: 1502–1507.

58. Czaja AJ and Freese DK; American Association for the Study of Liver Disease: Diagnosis and treatment of autoimmune hepatitis. Hepatology (2002) 36: 479–497.

59. Montano-Loza AJ, Carpenter HA and Czaja AJ: Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology (2007) 46: 1138–1145.

60. Montano-Loza AJ, Carpenter HA and Czaja AJ: Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int (2007) 27: 507–515.

61. Czaja AJ and Carpenter HA: Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int (2003) 23: 116–123.

62. Montano-Loza AJ, Carpenter HA and Czaja AJ: Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol (2007) 102: 1005–1012.

63. Czaja AJ, Menon KV and Carpenter HA: Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology (2002) 35: 890–897.

64. Seela S, Sheela H and Boyer JL: Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int (2005) 25: 734–739.

65. Johnson PJ, McFarlane IG and Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 333: 958–963.

66. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM and van Bodegraven AA: Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol (2006) 101: 1390–1392.

67. Heneghan MA, Norris SM, O'Grady JG, Harrison PM and McFarlane IG: Management and outcome of pregnancy in autoimmune hepatitis. Gut (2001) 48: 97–102.

68. Heneghan MA, Allan ML, Bornstein JD, Muir AJ and Tendler DA: Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol (2006) 45: 584–591.

69. Czaja AJ and Carpenter HA: Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci (2006) 51: 968–975.

70. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T and Makino I: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol (1998) 13: 490–495.

71. Czaja AJ, Carpenter HA and Lindor KD: Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a

randomized placebo-controlled treatment trial. Hepatology (1999) 30: 1381–1386.

72. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP and Strassburg CP: Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant (2004) 18: 62–69.

73. González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB and Wiesner RH: Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl (2001) 7: 302–310.

74. Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, Farahmand H, Gigou M, Fèray C, Reynès M and Bismuth H: Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol (1999) 30: 131–141.

75. Duclos-Vallée JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, Karam V, Hurtova M, Feray C, Reynes M, Bismuth H and Samuel D: A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut (2003) 52: 893–897.

76. Czaja AJ and Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol (2004) 40: 646–652.

77. Ryder SD, Koskinas J, Rizzi PM, McFarlane IG, Portmann BC, Naoumov NV and Williams R: Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology (1995) 22: 718–722.

78. Miyake Y, Sakaguchi K, Tanaka H, Nakamura S, Kobayashi Y, Fujioka S, Iwasaki Y and Shiratori Y: Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern Med (2005) 44: 949–953.

79. Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, Granito A, Ferrari R, Mantovani V, Lenzi M and Bianchi FB: Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol (2005) 11: 1862–1866.

80. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR and Heathcote EJ: Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology (2005) 42: 53–62.

81. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG and Heneghan MA: Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol (2006) 45: 575–583.